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1 C
2 Creatine
3 LOUISE DELDICQUE, MARC FRANCAUX
4 Muscle and Exercise Physiology Research Group, Institute
5 of Neuroscience, Universite´ catholique de Louvain,
6 Louvain-la-Neuve, Belgium
7 Synonyms
8 (a-Methylguanido)acetic acid; 2-(carbamimidoyl-
9 methyl-amino)acetic acid; Methyl glycocyamine;
10 Methylguanidoacetic acid; N-(aminoiminomethyl)-
11 N-methyl-glycine; N-amidinosarcosine; N-guanyl-
12 N-methylglycine; N-methyl-N-guanylglycine
13 Definition
14 Creatine is a nonessential dietary element found in high
15 abundance in meat and fish. Because of its molecular
16 structure, creatine is a member of the ▶ guanidino acid
17 family. It is not an amino acid! Normal daily intake of
18 creatine from an omnivorous diet approximates 1 g [1].
19 However, creatine is also synthesized within the body,
20 primarily in the liver, from two amino acids by a two-
21 step reaction at a rate of about 1 g per day. In the first step
22 catalyzed by arginine:glycine amidinotransferase,
23 guanidinoacetate is formed from arginine and glycine. In
24 the second step, a methyl group of S-adenosylmethionine
25 is transferred to guanidinoacetate and creatine is formed.
26 Approximately 120 g of creatine is found in a 70-kg
27 male, 95% in skeletal muscle. Total creatine exists as both
28 free creatine and phosphorylcreatine. The highest levels of
29 creatine and phosphorylcreatine are found in skeletal
30 muscle, heart, spermatozoa, and photoreceptors cells of
31 the retina. Intermediate levels are found in brain, brown
32 adipose tissue, intestine, endothelial cells, and macro-
33 phages, and low levels are found in lung, spleen, kidney,
34 liver, white adipose tissue, blood cells, and serum.
35 Creatine is an important source of chemical energy for
36 muscle contraction because it can undergo phosphoryla-
37 tion with the formation of phosphorylcreatine, and
38 reversible, with donation of the phosphate group to ADP
39 to form ATP. This reaction is catalyzed by the enzyme
40▶ creatine kinase and is a rapid source of high-energy
41phosphate for high-intensity, short-duration physical
42activity. The initial idea for creatine supplementation in
43athletes was improving the energy storage under the form
44of intramuscular phosphorylcreatine.
45Creatine kinase activity is higher in skeletal muscle
46than in others tissues. Evidence exists that the role of the
47creatine/phosphorylcreatine shuttle system also plays an
48essential role in energy homeostasis in the heart, brain,
49and retina to ensure proper development and function.
50Mechanism of Action
51Since the paper of Roger Harris and collaborators in 1992
52who reported for the first time beneficial effects of creatine
53supplementation, creatine has become one of the most
54popular dietary supplements in the world. Synthetic
55supplements exist as creatine monohydrate or various
56creatine salts, such as creatine citrate or creatine pyruvate,
57the latter being more soluble than creatine monohydrate.
58Muscle creatine content averages 110–120 mmol/kg
59dry mass and can be increased up to 130–160 mmol/kg
60dry mass after creatine supplementation, which represents
61an increase of about 15–30%. Two strategies of supple-
62mentation exist. In most conditions, 20 g of creatine is
63ingested every day for 5 days; thereafter, 3–5 g is consumed
64daily to maintain muscle uptake. A second strategy
65omits the loading phase. In this case, the rise in muscle
66creatine content is slower, but reaches the same level after
67about 15 days.
68To date, several hundred studies have been conducted
69to evaluate the efficacy of creatine supplementation for
70improving exercise performance. Nearly 70% of these
71studies have reported a significant improvement in exer-
72cise capacity. The gain in performance can reach up
73to 10% or 15% depending on the variable of interest,
74on the exercise mode, and on the exercise intensity.
75Typically, creatine supplementation seems to be effective
76in high-intensity, short-duration exercise wherein
77phosphorylcreatine availability is a limiting factor and
78not in other situations like in endurance events.
79Most, if not all, commercial and anecdotal claims of
80the beneficial effects of creatine supplementation are
81focused on the increase in muscle strength and muscle
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82 protein mass. Several scientific publications have also
83 emphasized the increase in strength and the higher muscle
84 protein content associated with the increase in body mass
85 or fat-free mass. The pertinent question for researchers
86 and practitioners is whether there is sufficient experimen-
87 tal evidence to support these allegations and what are the
88 mechanisms behind.
89 After a few weeks of creatine supplementation, the
90 average increase in body mass reported in the literature
91 amounts to 1–2 kg, or 1–2.3% of total body mass,
92 although about 30% of published articles do not report
93 any change. In well-controlled laboratory conditions, cre-
94 atine supplementation has been shown to improve muscle
95 strength by about 5–20%.
96 Several hypotheses have been proposed to explain
97 these effects on lean body mass and muscle strength.
98 Creatine per se could induce muscle hypertrophy due to
99 water retention since cellular water content may influence
100 protein metabolism. Creatine has been shown to increase
101 total body water including intracellular water. However,
102 the relative volume of the body water compartments
103 remains unchanged after creatine supplementation.
104 Therefore the gain in body mass cannot be attributed to
105 water retention alone but to an increase in dry matter
106 accompanied by a normal water volume.
107 Evidence accumulated over the past 15 years suggests
108 that the primary mechanism by which creatine exerts its
109 ▶ anabolic effect in healthy subjects who are weight train-
110 ing is by allowing them to work at a higher proportion of
111 their maximal voluntary contraction force and thus
112 increase the training stimulus. However, this mechanism
113 may not explain all the observations like the higher
114 force production observed in patients suffering from
115 myopathy (see below).
116 The increase in lean body mass after creatine supple-
117 mentation could be the result of a larger protein synthesis
118 or a decrease in protein breakdown or both together.
119 However, it has been reported that creatine had no effect
120 on skeletal muscle protein synthesis and breakdown,
121 whether at rest or after resistance exercise suggesting that
122 short-term creatine loading does not have a significant
123 effect on measures of skeletal muscle protein balance.
124 Other experiments conducted on a longer period of
125 time reported that creatine supplementation resulted in
126 larger increases in type I, IIA, IIAB muscle fiber cross-
127 sectional area compared with placebo after 12 weeks of
128 heavy resistance training and after 2 weeks of leg immo-
129 bilization followed by 10 weeks of rehabilitation. Creatine
130 supplementation also leads to greater increases in type
131 I and II MHC (myosin heavy chain) mRNA abundance
132 and protein content after 12 weeks of resistance training,
133suggesting that an increase inMHC synthesis may account
134in part for the greater increase in muscle size with creatine
135supplementation. Creatine supplementation has also been
136shown to amplify the increase in ▶ satellite cell number
137and myonuclei concentration in human skeletal muscle
138fibers during 4–16 weeks of resistance training.
139In vitro experiments were conducted with the goal of
140understanding the molecular mechanisms by which crea-
141tine stimulates muscle growth. The results indicated that
142Akt/PKB and p38 MAPK and their downstream targets
143play essential roles in the enhancement of ▶myotubes
144differentiation by creatine [2]. But, the question remains
145as to how creatine activates the Akt/PKB and the p38
146MAPK pathways.
147There is a close functional coupling between the▶ sar-
148coplasmic calcium ATPase and the creatine kinase system.
149This functional coupling may explain the faster skeletal
150muscle relaxation time observed after creatine loading in
151humans, and the impairment in skeletal muscle excita-
152tion/contraction in a mouse model lacking cytosolic and
153mitochondrial creatine kinase. The increase in calcium
154uptake may explain the reduction in cytosolic calcium
155accumulation and enhanced survival of muscular dystro-
156phic myotubes incubated with creatine.
157Clinical Use
158Creatine supplementation has become one of the most pop-
159ular ergogenic aids among athletes for enhancing acute per-
160formance or training adaptations. In a clinical perspective, the
161potential exists for creatine to be a therapeutic replacement
162strategy in neurological and/or muscular diseases as the con-
163centration of phosphorylcreatine in resting skeletal muscle is
164lower in patients with muscular dystrophy/congenital myop-
165athies, inflammatory myopathies, Huntington’s disease,
166Friedrich’s ataxia, and mitochondrial cytopathies, and with
167normal aging. Brain phosphorylcreatine concentration is
168lower in patientswithmitochondrial cytopathy, cerebral ische-
169mia, and bipolar affective disorders. Creatine supplementation
170of those patients may result in a partial restoration
171of intracellular creatine concentration, an increase in type II
172muscle fiber diameter, improved exercise capacity, increased
173muscle strength, reduced headache frequency, normalization
174of electrocardiogram abnormalities, etc., depending on the
175type and the severity of the disorder.
176Diagnostics
177Whereas the determination of the ▶ isoenzymes of crea-
178tine kinase or phosphorylcreatine kinase in plasma has
179been extensively studied and used in the diagnosis of
180acutemyocardial infarction, this paragraphwill be focused
181on the use of creatine itself and its precursors in creatine
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182 deficiency syndromes [3] and in neuromuscular diseases
183 [4]. Creatine deficiency syndromes represent a group of
184 inborn errors of creatine synthesis (arginine:glycine
185 amidinotransferase deficiency and guanidinoacetate
186 methyltransferase deficiency) and transport (creatine
187 transporter deficiency). All three defects can be diagnosed
188 by in vivo nuclear magnetic resonance spectroscopy of the
189 brain, which shows a severe reduction or absence of crea-
190 tine. Laboratory investigations for the diagnosis start with
191 the analysis of guanidinoacetate, creatine, and creatinine
192 in plasma and urine. Measurement of guanidinoacetate,
193 creatine concentrations, and calculation of creatine/creat-
194 inine and guanidinoacetate/creatinine ratios in urine
195 makes possible the identification of arginine:glycine
196 amidinotransferase (low creatine with low
197 guanidinoacetate excretion) and guanidinoacetate
198 methyltransferase deficiencies (low creatine with high
199 guanidinoacetate excretion), as well as creatine trans-
200 porter defects (high creatine/creatinine and
201 guanidinoacetate/creatinine ratios in urine). Moreover,
202 enzyme assays for arginine:glycine amidinotransferase or
203 guanidinoacetate methyltransferase, or a creatine uptake
204 assay for the transporter defect can be performed. DNA
205 mutation analysis of the genes involved can prove the
206 defects at the molecular level. To diagnose patients with
207 creatine transporter deficiency, mutation analysis may be
208 the only choice.
209 People with neuromuscular disorders such as mito-
210 chondrial cytopathies, Huntington’s disease,
211inflammatory myopathies, and Duchenne dystrophy can
212have lower skeletal muscle total creatine and phosphocre-
213atine concentrations than control subjects. This may be
214due to lower creatine transporter content or an impair-
215ment of energy charge, a measure of the relative amounts
216of adenosine tri-, di-, and monophosphate in the cell, in
217these patients. Creatine, phosphocreatine, and adenosine
218tri-, di-, andmonophosphate can be determined inmuscle
219biopsies by biochemical analyses or by nuclear magnetic
220resonance spectroscopy.
221It is of note that guanidinoacetate methyltransferase
222and arginine:glycine amidinotransferase deficiencies and
223some neuromuscular disorders are treatable by, or at least
224benefit from, oral creatine supplementation, but patients
225with creatine transporter deficiency do not respond to this
226type of treatment.
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